Letters by company
MEI Pharma Inc
2 letters discussing MEIP. Everything written about it on this site is on its ticker page.
- GreenWood Investors First Half 2025 Letter: Durability & Balance GreenWood Investors argues that board-level ownership and durable industry tailwinds are driving value creation at Leonardo and CTT, while management teams expand defense systems, e-commerce logistics and banking opportunities. The firm launched a Swatch coinvestment, pressed for governance reform, and repositioned MEI Pharma around a Litecoin treasury strategy after its clinical assets failed to meet the board’s threshold. First Half 2025 CTTOF $686MFINMF $32BSWGAF $11B
- GreenWood Investors Fundamental Momentum GreenWood centers its activist portfolio on owner-minded management at Leonardo, CTT and MEI Pharma, arguing that governance work can improve capital allocation and operating execution. It added PDD and Rentokil after market dislocations, while backing NexGen Energy and Bolloré’s indirect exposure to Universal Music Group. 2023 BOIVF $12BCTTOF $686MFINMF $32B